Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Chuikyo OKs Listing of Harvoni, Peak Sales Put at 119 Billion Yen in 2nd Year
The Central Social Insurance Medical Council (Chuikyo) on August 26 approved the NHI price listing of Gilead Sciences K.K.’s chronic hepatitis C drug Harvoni (ledipasvir + sofosbuvir), which is expected to rack up 119 billion yen in the second year…
To read the full story
Related Article
- Harvoni, Yervoy, Other New Drugs Hit Japan Market
September 1, 2015
- Panel OKs Medical Subsidy for Harvoni, Monthly Copay Up to 20,000 Yen
August 28, 2015
- Commentary: Spiking Drug Prices Behind Harvoni Pricing Spat at Chuikyo
August 28, 2015
- Chuikyo Reps Trade Barbs over Pricing of Harvoni, Listing OK'ed by a Whisker
August 27, 2015
REGULATORY
- Japan to Ease Olanzapine Diabetes Contraindication for Antiemetic Use
July 31, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…